Skip to main content
. Author manuscript; available in PMC: 2019 Jul 8.
Published in final edited form as: Leuk Res. 2018 Feb 14;67:67–74. doi: 10.1016/j.leukres.2018.02.008

Fig. 3.

Fig. 3.

Results from the Euro-SKI study (ASH 2016) (a) Molecular recurrence-free survival (n = 755 of 772 persons enrolled); Euro-SKI study (ASH 2016) (b) Prognostic modeling (n = 405, imatinib);Euro-SKI study (ASH 2016).